Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME2PKB)

• Drug Name: D[Lys8(5/6-Flu)]VT Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44320997
  TTD Drug ID: DME2PKB

Molecule-Related Drug Atlas

Drug(s) Targeting Vasopressin V1b receptor (V1BR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[2]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[3]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[4]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[5]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
ABT-436	DMNAU1V	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
ARGENINE VASOPRESSIN	DM8KN0Q	Discovery agent	N.A.	Investigative	[8]
D[Arg4,Orn8]VP	DM8D4QT	Discovery agent	N.A.	Investigative	[8]
D[Leu4,Lys8]VP	DMDBU7Q	Discovery agent	N.A.	Investigative	[8]
D[Arg4,Lys8]VP	DM69OVM	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Vasopressin V1a receptor (V1AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[2]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[9]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[10]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[11]
Felypressin	DMHLP9C	Localisation	N.A.	Approved	[12]
Terlipressin	DMT9FH3	Hypertension	BA00-BA04	Approved	[13]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[5]
Balovaptan	DMKMTDG	Autism spectrum disorder	6A02	Phase 3	[14]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[15]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[16]

Drug(s) Targeting Oxytocin receptor (OTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[2]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[17]
Carbetocin	DMUSLW3	Postpartum haemorrhage	JA43	Approved	[12]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[18]
Retosiban	DMOYGZF	Preterm labour	JB00	Phase 3	[19]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[16]
Barusiban	DMWI0X3	Androgen deficiency	5A81.1	Phase 2	[20]
FE-202767	DMDGZ1C	Erectile dysfunction	HA01.1	Phase 2	[17]
GSK-557296	DM3ZL2O	Premature ejaculation	HA03.0Z	Phase 2	[21]
Pyrrolidine derivative 13	DM3VA8P	N. A.	N. A.	Patented	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Inhibitor	[1]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Inhibitor	[1]
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88.
• [2] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [3] New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
• [4] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [5] The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
• [6] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [7] The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
• [8] Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
• [9] Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
• [10] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [11] Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
• [12] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [13] Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
• [14] Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
• [15] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [16] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
• [18] Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
• [19] The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
• [20] The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
• [21] Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
• [22] A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.